الأخبار والآراء
ملخص للأخبار والآراء التي تؤثر على حياة الأشخاص المصابين بسرطان الرئة الإيجابي لـ ALK
Demographics of UK ALK-positive patients
At our September 2026 conference, we published our report on the demographics of ALK-positive patients in the UK. This the first report that catelogues the characteristics of UK patients and confirms that at diagnosis most patients were fit, non-smokers in the their mid fifties.
LORIN Study - Unresectable becomes Resectable
In a small study (NCT05740943), out of 24 Stage III ALK+LC patients whose tumors were initially deemed completely unresectable, 75% (18 patients) improved enough after 3 cycles of lorlatinib to undergo successful conversion surgery. [Abstract presented at ASCO]
Antibody-drug conjugates in precision medicine
ADCs have delivered truly transformative benefits in selected clinical contexts, yet their overall impact remains uneven and far from fully realised.
This is a review of ADC successes and setbacks to mechanisms of efficacy, resistance, and toxicity, and discusses how biomarkers, ADC combinations, next-generation platforms, and curative-intent strategies should shape precision oncology frameworks.
Upfront SRS
A report at ASCO 2026 (NCT05236946) showed that upfront SRS reduced the risk of CNS progression by 65% v delaying SRS until patient becomes symptomatic.
This supports the Charity's position that asymptomatic patients should receive routine brain scans every 6 months to identify any brain mets whilst they are small and few in number.
Questions to Ask Your Healthcare Team
ALK Positive UK has published a new guide to help patients prepare for medical consultations and understand key questions to ask during appointments.
The new booklet, Talking Points: A good practice guide on what questions to ask your healthcare team, has been developed by the Charity with input from clinical experts and reviewers from the ALK‑positive lung cancer community. It has also carries the PIF Tick, the UK’s independent quality mark for trusted health information.
Copies available on request.
National Institute for Health and Care Excellence
The cost-effective threshold was increased from £20K - £30K per quality-adjusted life year (QUALY) to £25K - £35K in April 2026. The new threshold is part of a broader effort to enhance the UK's position in the life sciences sector and support innovation in healthcare.
Venous Thromboembolism
Patients with ALK rearrangements have a 3–5-fold higher risk of VTE than those with other oncogenic drivers.
Early detection and proactive management is essential and physicians should actively assess for signs and symptoms of thrombosis at diagnosis and throughout the follow up period.
Below is a link to a summary of a study and the full report is available on request.
Professor Alastair Greystoke
We are delighted to announce that Professor Alastair Greystoke is our new Honorary Clinic Advisor, succeeding Professor Popat who is standing down after 7 years.
Professor Greystoke is Professor of Precision Oncology at Newcastle University and Honorary Medical Oncologist at Newcastle's Northern Centre for Cancer Care.
Alastair has been very supportive of the charity for many years.
Emma describes her cancer as being like a suitacse
Emma Britton took part in the launch of Lung Cancer Europe's report on Mental Health and Lung Cancer. Read what Emma had to say about the stress and anxiety of living with lung cancer and her moving description of her Stage 4 lung cancer as being like an old suitace.
Liquid Biopsies for suspected advanced lung cancer
NHS England has made circulating tumour DNA (ctDNA) testing available for all eligible patients who have a suspected diagnosis of advanced non-small cell lung cancer (NSCLC).
The Christie's ALKnowledge website has a blog about this important step in speeding up the diagnosis and treatment of patients with ALK+ LC and other oncogene-driven LCs.
تردد تصوير الرأس بالرنين المغناطيسي
من المرجح أن يُصاب ثلاثة من كل خمسة مرضى إيجابيين لجين ALK بنقائل دماغية (أورام) خلال ثلاث سنوات. وترى المؤسسة الخيرية أنه ينبغي إجراء فحوصات بالرنين المغناطيسي كل ستة أشهر قبل ظهور الأعراض، حتى يُمكن علاج النقائل عندما تكون صغيرة وقليلة العدد.
لقد تم اختيار ملخصنا الذي يدعو إلى إعداد بروتوكول وطني لعرضه في المؤتمر السنوي لائتلاف سرطان الرئة في المملكة المتحدة.
الحمل والعلاجات المستهدفة
قد تُطيل العلاجات المُوجَّهة (مثبطات التيروزين كيناز - TKIs) الأعمار بشكل ملحوظ، ومن المتوقع أن يُفكِّر المزيد من النساء في سن الإنجاب في الحمل. قد تحدث حالات حمل غير مُخطط لها، وقد تُشخَّص النساء الحوامل بالفعل بسرطان الدم الليمفاوي الحاد (LC) المُؤيَّد لجين ALK.
قد تؤثر مثبطات التيروزين كيناز على الجنين، ونحن بصدد إعداد نصائح حول هذا الموضوع. في هذه الأثناء، يُرجى التواصل معنا لمناقشة هذا الأمر.
الجيل الأول
All About ALK-positive Lung Cancer
This paper has been produced by Elena Klenova, Emeritus Professor, School of Life Sciences, University of Essex, and an ALK-positive patient.
Although it is a beginner's guide, it is quite technical in parts. However, section 11 (Current and Future Treatment Perspectives) and section 12 (Discussion on Socio-Economic, Health and Research Challenges) are well-worth reading.
تمت الموافقة على لورلاتينيب
لورلاتينيب هو مثبط كيناز التيروزين (TKI) من الجيل الثالث المستخدم لعلاج سرطان الرئة المتقدم الإيجابي لـ ALK.
في 7 أكتوبر 2025، وافق المعهد الوطني للتميز في الرعاية الصحية (NICE) على استخدامه كخط أول للمرضى حديثي التشخيص في إنجلترا وويلز. وكان قد حصل سابقًا على موافقة في اسكتلندا.